Precigen, Inc. is a biotechnology company specializing in the development of synthetic biology technologies. Headquartered in Germantown, Maryland, the company was founded in 1998 by Thomas David Reed. It operates across multiple divisions, each focusing on different aspects of biopharmaceutical advancements, agricultural biotechnology, and gene therapy.
A Multi-Segment Approach to Biotechnology
Precigen is structured into three key segments: Biopharmaceuticals, Exemplar, and Trans Ova. Each of these divisions plays a crucial role in the company’s mission to develop cutting-edge scientific solutions in healthcare and agricultural biotechnology.
-
Biopharmaceuticals: This segment is dedicated to developing next-generation gene and cell therapies, utilizing precision technology to address critical diseases. The company focuses on treating conditions in areas such as immuno-oncology, autoimmune disorders, and infectious diseases. A significant part of this effort includes proprietary microbe-based biopharmaceuticals, which facilitate the expression and localized delivery of therapeutics that modify disease processes.
-
Exemplar: The Exemplar division specializes in producing advanced research models and services for use in healthcare research. These models are essential tools for medical and pharmaceutical research, helping scientists and companies accelerate the development of new treatments and therapies.
-
Trans Ova: This division is centered on bovine reproductive technologies, providing innovative solutions in the field of animal genetics. By leveraging advanced reproductive techniques, Trans Ova helps improve breeding and genetic outcomes in cattle, supporting the agricultural industry.
A Focus on Innovation and Growth
Precigen has built a reputation for innovation in synthetic biology, particularly in gene and cell therapy. The company’s proprietary technologies and precision-based approaches position it as a leader in addressing some of the most pressing challenges in modern medicine.
Its research and development efforts are aimed at creating groundbreaking treatments that go beyond conventional therapies. By integrating synthetic biology with precision medicine, Precigen is working towards therapies that are not only effective but also tailored to individual patients.
As the biotechnology landscape continues to evolve, Precigen remains committed to expanding its portfolio and enhancing the potential of synthetic biology in both healthcare and agricultural applications.
